Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery.

Publication ,  Journal Article
Mittra, RA; Dev, S; Nasir, MA; Toth, CA
Published in: Ophthalmology
March 1997

PURPOSE: The authors studied the effect of a direct acting antithrombin agent, desulfatohirudin variant 1 (Revasc, Ciba-Geigy, Ltd., Basel, Switzerland), on postoperative fibrin formation after cataract surgery in rabbits. METHODS: Phacoemulsification was performed in a masked fashion on 28 eyes of 28 New Zealand white rabbits. Ten control group eyes had lactated Ringer's solution in the infusion and an intracameral injection (approximately 1.5 ml) at the end of the case. Ten group 1 eyes received hirudin 100 micrograms/ml in the infusion and intracameral injection. Eight group 2 eyes had 100 micrograms/ml hirudin in the intracameral injection only. Using slit-lamp examination, all eyes were graded for the amount of fibrin and intraocular hemorrhage in a masked fashion on postoperative day 1. RESULTS: Comparison of the mean postoperative fibrin grade (0-4) in group 1 (mean = 0.3), group 2 (mean = 0.25) and the control group (mean = 3.4) revealed a statistically significant difference between hirudin-treated and control eyes (P = 0.0002 for group 1, P = 0.0005 for group 2). No intraocular hemorrhage was noted in any group. CONCLUSIONS: Recombinant hirudin significantly decreases postoperative fibrin formation in a rabbit cataract extraction model. Intracameral injection of hirudin alone appears to be at least as effective as infusion of hirudin throughout the case. With further study, this agent has potential for use in cataract surgery on patients known to be at high risk for postoperative fibrin formation.

Duke Scholars

Published In

Ophthalmology

DOI

ISSN

0161-6420

Publication Date

March 1997

Volume

104

Issue

3

Start / End Page

558 / 561

Location

United States

Related Subject Headings

  • Thrombolytic Therapy
  • Recombinant Proteins
  • Rabbits
  • Postoperative Complications
  • Phacoemulsification
  • Ophthalmology & Optometry
  • Injections
  • Humans
  • Hirudins
  • Fibrinolytic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mittra, R. A., Dev, S., Nasir, M. A., & Toth, C. A. (1997). Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. Ophthalmology, 104(3), 558–561. https://doi.org/10.1016/s0161-6420(97)30275-9
Mittra, R. A., S. Dev, M. A. Nasir, and C. A. Toth. “Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery.Ophthalmology 104, no. 3 (March 1997): 558–61. https://doi.org/10.1016/s0161-6420(97)30275-9.
Mittra RA, Dev S, Nasir MA, Toth CA. Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. Ophthalmology. 1997 Mar;104(3):558–61.
Mittra, R. A., et al. “Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery.Ophthalmology, vol. 104, no. 3, Mar. 1997, pp. 558–61. Pubmed, doi:10.1016/s0161-6420(97)30275-9.
Mittra RA, Dev S, Nasir MA, Toth CA. Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. Ophthalmology. 1997 Mar;104(3):558–561.
Journal cover image

Published In

Ophthalmology

DOI

ISSN

0161-6420

Publication Date

March 1997

Volume

104

Issue

3

Start / End Page

558 / 561

Location

United States

Related Subject Headings

  • Thrombolytic Therapy
  • Recombinant Proteins
  • Rabbits
  • Postoperative Complications
  • Phacoemulsification
  • Ophthalmology & Optometry
  • Injections
  • Humans
  • Hirudins
  • Fibrinolytic Agents